Wall Street Got Oscar All Wrong

Oscar Health's (OSCR) Q2 performance, including its 91.1% medical loss ratio and subsequent stock decline, is presented as a market misinterpretation, largely due to a one-time retroactive risk adjustment rather than fundamental operational issues. The company demonstrated strong underlying metrics, including 29% revenue growth, 28% membership growth, improved SG&A, and a robust balance sheet with $5.4 billion in cash. Oscar's distinct digital-first, ACA-focused model and increasing free cash flow per share differentiate it from peers. Despite trading at a significant discount (0.14x forward EV/sales), the article suggests the market is overlooking Oscar's strategic advantages and operational improvements, creating a potential asymmetric investment opportunity driven by fear rather than fundamentals.

Analysis

Oscar Health's (OSCR) second-quarter performance has been significantly misinterpreted by the market, leading to a valuation disconnect. The reported 91.1% Medical Loss Ratio (MLR), a primary driver of the stock's approximate 40% decline, was heavily skewed by a one-time, industry-wide retroactive risk adjustment payment; normalizing for this suggests a more stable underlying MLR of around 85.1%. Despite the headline loss, the company's core operational metrics remain robust, evidenced by 29% year-over-year revenue growth to $2.86 billion and 28% membership growth. Furthermore, Oscar is demonstrating significant operating leverage through its proprietary technology stack, achieving an improved SG&A ratio of 18.7% and realizing $60 million in annualized savings. This operational model and exclusive focus on the ACA exchange fundamentally differentiates it from peers like Centene (CNC), which experienced a $2.4 billion margin blowout due to its complex, multi-line business structure. Oscar's balance sheet remains strong with $5.4 billion in cash and investments, and a notable turnaround in Free Cash Flow per Share to a positive $3.46 provides further evidence of underlying financial health. The company's forward EV/Sales multiple of 0.14x represents a steep discount, suggesting the market is pricing in a structural failure rather than recognizing the platform's improving unit economics and embedded optionality. Key risks remain, primarily the potential 2025 expiration of enhanced ACA subsidies, which could reduce enrollment by 25-30% and pressure margins.

Key Decisions for Investors

• Given the substantial valuation discount and strong underlying fundamentals like 29% revenue growth and positive free cash flow per share, investors may view the current share price as an asymmetric opportunity resulting from a market overreaction to a non-operational accounting adjustment.
• It is critical to monitor upcoming quarterly reports for evidence of MLR normalization and continued SG&A compression, as these will be the key validation points for the thesis that Q2's performance was an anomaly.
• Positioning in Oscar Health requires careful consideration of significant policy risk, specifically the potential expiration of enhanced ACA subsidies in 2025, which the company estimates could trigger a 25-30% decline in enrollment.
• Evaluate Oscar not as a traditional insurer but as a technology-enabled platform, focusing on its strategic agility and improving unit economics relative to more complex competitors like Centene.